Fresenius Ventures Fund I

Fresenius Ventures

cb Email

Status

ACTIVE

Global HQ

Bad Homburg, Germany

Countries of investment

United States
Germany
United Kingdom
France
Netherlands
Switzerland
Israel
Sweden
Denmark
Belgium
Ireland
Italy
Spain
Austria

Investment stages

Seed
Series A
Series B
Series C
Growth

Industries

Biopharmaceuticals
Medical Devices
Digital Healthcare
Precision Nutrition
Microbiome
Healthcare Services

About
Fresenius Ventures is a Bad Homburg-based corporate venture capital firm focused on backing healthcare founders shaping the future of care. Their focus spans biopharmaceuticals, medical devices, digital healthcare, precision nutrition, and microbiome research across United States, Germany, United Kingdom, France, Netherlands, Switzerland, Israel, Sweden, Denmark, Belgium, Ireland, Italy, Spain, and Austria. The firm supports healthcare founders from seed through growth stages.

Min check size: $2M
Max check size: $25M
Fund size: Unlock
NPS: Unlock

Investment Thesis

Fresenius Ventures is a seed to growth stage corporate venture capital firm deploying capital across biopharmaceuticals, medical devices, digital healthcare, precision nutrition, microbiome research, and healthcare services sectors. They invest €200M+ over five years in healthcare founders across early to growth stages, offering medical, regulatory, and operational expertise alongside access to Fresenius's global clinical, scientific, and academic networks. The firm differentiates itself as the corporate venture arm of Fresenius Group ($22.6B revenue in 60+ countries), providing portfolio companies unmatched scale-up capabilities across BioPharma, MedTech, and Care Provision platforms.

Lead investor: Unlock
Co Invest: Unlock
Number of exits: Unlock
Preferred contact method: Unlock

Manager's Experience

Founded in 2025 as the corporate venture capital arm of Fresenius Group ($22.6B revenue in 2025 operating in 60+ countries). Led by Dr. Thomas Michael Thestrup (Head of Fresenius Ventures, formerly of Angelini Ventures, 15+ years of healthcare and venture experience). Committed to invest more than €200M over five years. Based in Bad Homburg, Germany with global reach across Europe, US, and Israel. Combines medical, regulatory, and operational expertise with access to Fresenius's clinical, scientific, and academic networks. Investment focus on precision nutrition, microbiome research, new modalities, and digital care solutions adjacent to Fresenius's (Bio)Pharma, MedTech, and Care Provision platforms.